LT1951663T - (r)-arilalkilamino dariniai ir juos turinčios farmacinės kompozicijos - Google Patents

(r)-arilalkilamino dariniai ir juos turinčios farmacinės kompozicijos

Info

Publication number
LT1951663T
LT1951663T LTEP06819736.7T LT06819736T LT1951663T LT 1951663 T LT1951663 T LT 1951663T LT 06819736 T LT06819736 T LT 06819736T LT 1951663 T LT1951663 T LT 1951663T
Authority
LT
Lithuania
Prior art keywords
arylkylamino
derivatives
pharmaceutical compositions
compositions containing
pharmaceutical
Prior art date
Application number
LTEP06819736.7T
Other languages
English (en)
Inventor
Marcello Allegretti
Alessio Moriconi
Andrea Aramini
Maria Candida Cesta
Andrea Beccari
Riccardo Bertini
Original Assignee
Dompé Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompé Farmaceutici S.P.A. filed Critical Dompé Farmaceutici S.P.A.
Publication of LT1951663T publication Critical patent/LT1951663T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/76—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
LTEP06819736.7T 2005-11-24 2006-11-24 (r)-arilalkilamino dariniai ir juos turinčios farmacinės kompozicijos LT1951663T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05111257 2005-11-24
PCT/EP2006/068867 WO2007060215A2 (en) 2005-11-24 2006-11-24 (r)-arylkylamino derivatives and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
LT1951663T true LT1951663T (lt) 2016-11-10

Family

ID=37865701

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP06819736.7T LT1951663T (lt) 2005-11-24 2006-11-24 (r)-arilalkilamino dariniai ir juos turinčios farmacinės kompozicijos

Country Status (19)

Country Link
US (1) US8026367B2 (lt)
EP (1) EP1951663B1 (lt)
JP (2) JP5374157B2 (lt)
CN (1) CN101360706B (lt)
AU (1) AU2006316452B2 (lt)
CA (1) CA2629935C (lt)
CY (1) CY1118109T1 (lt)
DK (1) DK1951663T3 (lt)
ES (1) ES2597843T3 (lt)
HK (1) HK1127592A1 (lt)
HR (1) HRP20161260T1 (lt)
HU (1) HUE031466T2 (lt)
LT (1) LT1951663T (lt)
PL (1) PL1951663T3 (lt)
PT (1) PT1951663T (lt)
RS (1) RS55192B1 (lt)
RU (1) RU2458051C2 (lt)
SI (1) SI1951663T1 (lt)
WO (1) WO2007060215A2 (lt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8793748B2 (en) * 2007-07-26 2014-07-29 The Directv Group, Inc. Method and system for controlling communication between a user device and a content delivery network
US20090028317A1 (en) * 2007-07-26 2009-01-29 The Directv Group, Inc. Method and system for providing callbacks from a user device using an ip network
ATE501140T1 (de) * 2007-10-18 2011-03-15 Dompe Spa (r)-4-(heteroaryl)phenylethylderivate und pharmazeutische zusammensetzungen damit
NZ594140A (en) 2008-12-22 2013-09-27 Chemocentryx Inc C5ar antagonists
SI2585064T1 (sl) 2010-06-24 2017-08-31 Chemocentryx, Inc. Antagonisti C5AR
TW201329025A (zh) 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
PT3200791T (pt) 2014-09-29 2020-05-06 Chemocentryx Inc Processos e intermediários na preparação de antagonistas c5ar
CN104623687B (zh) * 2015-03-11 2017-09-05 中国科学院上海高等研究院 利用美登醇制备的抗体药物偶联物及其制备方法和应用
CA3010735C (en) 2016-01-14 2023-06-13 Chemocentryx, Inc. Use of n-benzoyl-2-phenyl-3-phenylcarbamoyl-piperidin derivative for treating complement 3 glomerulopathy
EP3498269A1 (en) 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
TW202012396A (zh) * 2018-04-18 2020-04-01 美商德洛斯股份有限公司 具乙烯磺醯胺部分之k-ras調節劑
US20240180888A1 (en) 2021-03-17 2024-06-06 Dompe' Farmaceutici Spa C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP4059497A1 (en) 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP4397306A1 (en) 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. C5ar1 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62252755A (ja) * 1986-04-11 1987-11-04 Daikin Ind Ltd 新規ｎ−ベンジルベンズアミド誘導体およびこれを有効成分として含有する除草剤
US4861891A (en) * 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
JPH09301933A (ja) * 1996-05-14 1997-11-25 Sumika Fine Chem Kk アミン類の製造方法
US6020335A (en) * 1997-02-06 2000-02-01 Pfizer Inc (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents
NZ504465A (en) * 1997-10-14 2001-11-30 Welfide Corp 1-Phenylacylamino substituted piperazine derivatives which are 4-substituted by a heteroaryl group
US6337399B1 (en) * 1997-10-27 2002-01-08 Toyama Chemical Co., Ltd. Processes for producing 7-isoindolinequinolonecarboxylic derivatives and intermediates therefor, salts of 7-isoindolinequinolonecarboxylic acids, hydrates thereof, and composition containing the same as active ingredient
CN1294574A (zh) * 1997-12-15 2001-05-09 阿肯色大学评议会 杀真菌酰胺
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
AU5636900A (en) * 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
NZ525591A (en) * 2000-10-05 2004-04-30 Fujisawa Pharmaceutical Co Benzamide compounds as Apo B secretion inhibitors
ITMI20010395A1 (it) * 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
MXPA03009441A (es) * 2001-04-16 2004-02-12 Schering Corp Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc.
MXPA04003439A (es) * 2001-10-12 2004-07-08 Schering Corp Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc.
AU2003900587A0 (en) * 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
US20050222408A1 (en) * 2003-07-14 2005-10-06 University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
RU2006106920A (ru) * 2003-08-06 2007-09-20 Синомикс Инк. (Us) Гетеро-олигомерные вкусовые рецепторы t1r, клеточные линии, которые экспрессируют указанные рецепторы и вкусовые соединения
CN1918156B (zh) * 2003-12-22 2010-10-27 先灵公司 作为cxc-和cc-趋化因子受体配体的异噻唑二氧化物
WO2005070889A1 (en) * 2004-01-23 2005-08-04 E.I. Dupont De Nemours And Company Herbicidal amides
EP1776336B1 (en) 2004-03-23 2009-09-30 DOMPE' pha.r.ma s.p.a. 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
HUE031466T2 (hu) 2017-07-28
JP5374157B2 (ja) 2013-12-25
DK1951663T3 (en) 2016-10-10
EP1951663B1 (en) 2016-07-20
WO2007060215A2 (en) 2007-05-31
RU2008125433A (ru) 2009-12-27
EP1951663A2 (en) 2008-08-06
JP5730343B2 (ja) 2015-06-10
ES2597843T3 (es) 2017-01-23
JP2009517368A (ja) 2009-04-30
RS55192B1 (sr) 2017-01-31
AU2006316452B2 (en) 2013-01-10
CN101360706B (zh) 2013-10-02
SI1951663T1 (sl) 2016-10-28
RU2458051C2 (ru) 2012-08-10
HK1127592A1 (en) 2009-10-02
CN101360706A (zh) 2009-02-04
HRP20161260T1 (hr) 2016-11-18
JP2013173743A (ja) 2013-09-05
CA2629935A1 (en) 2007-05-31
PT1951663T (pt) 2016-10-03
PL1951663T3 (pl) 2017-01-31
AU2006316452A1 (en) 2007-05-31
US20090124664A1 (en) 2009-05-14
US8026367B2 (en) 2011-09-27
CY1118109T1 (el) 2017-06-28
WO2007060215A3 (en) 2007-10-04
CA2629935C (en) 2016-01-19

Similar Documents

Publication Publication Date Title
HK1244267A1 (zh) 包含(r)-n-甲基納曲酮的藥物組合物
IL190292A (en) History of pyridopyrimidinone and their pharmaceutical preparations
IL188941A0 (en) Pyrazinolyguanidine derivatives and pharmaceutical compositions containing the same
IL186738A0 (en) Pyrizole derivatives and pharmaceutical compositions containing the same
IL183919A0 (en) Triazolophthalazine derivatives and pharmaceutical compositions containing the same
IL189782A0 (en) Sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
IL194546A0 (en) Arylaminopyridine derivatives and pharmaceutical compositions containing them
IL188207A0 (en) Pyrrolidine derivatives and pharmaceutical compositions containing the same
HK1127592A1 (en) (r)-arylkylamino derivatives and pharmaceutical compositions containing them (r)-
IL188050A0 (en) Azaindazole derivatives and pharmaceutical compositions containing the same
IL192184A0 (en) Heterocyclic derivatives and pharmaceutical compositions containing the same
IL193240A0 (en) Dihydrodiazepine derivatives and pharmaceutical compositions containing the same
IL177168A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
IL191044A0 (en) Aminopyrimidine derivatives and pharmaceutical compositions containing the same
IL196033A0 (en) Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
IL190249A0 (en) Deazapurine derivatives and pharmaceutical compositions containing the same
IL196267A0 (en) Indole derivatives and pharmaceutical compositions containing the same
IL221323A0 (en) 1-methyl-1h- pyridin-2-one- phenanthridine derivatives and pharmaceutical compositions containing the same
IL177260A0 (en) Indazole derivatives and pharmaceutical compositions containing them
IL208497A0 (en) Pharmaceutical compositions containing erythropoietin and derivatives thereof
IL187603A0 (en) Piperazine derivatives and pharmaceutical compositions containing the same
IL187748A0 (en) Pharmaceutical compositions containing misoprostal
IL194738A0 (en) Piperazine derivatives and pharmaceutical compositions containing the same
IL183986A0 (en) Pharmaceutical compounds and compositions
IL193211A (en) Derivatives of Indzol-Troaril and pharmaceutical preparations containing them